论文部分内容阅读
目的研究培菲康与铋剂四联方案在老年消化性溃疡幽门螺杆菌感染患者中的临床治疗效果,为临床提供依据。方法选取2014年11月-2016年1月医院诊治的68例老年消化性溃疡幽门螺杆菌(HP)感染患者,随机分为对照组和试验组,每组34例;对照组采用铋剂四联方案治疗,试验组在对照组基础上联合培菲康辅助治疗,比较两组临床疗效。结果试验组治疗疗效率为91.18%,显著高于对照组的73.53%(P<0.05);两组患者治疗前血锌浓度差异无统计学意义;试验组治疗后2周、4周血锌浓度水平,显著低于对照组(P<0.05);试验组治疗后不良反应发生率为14.71%,显著低于对照组的35.92%(P<0.05)。结论老年消化性溃疡HP感染患者在铋剂四联方案治疗基础上联合培菲康辅助治疗效果理想,不良反应发生率低,值得推广应用。
Objective To study the clinical efficacy of the combination of pefloxacin and bismuth in the treatment of elderly patients with peptic ulcer infection of Helicobacter pylori and provide the basis for clinical study. Methods Sixty-eight elderly patients with peptic ulcer infection of Helicobacter pylori (HP) were selected from November 2014 to January 2016 in our hospital and randomly divided into control group and trial group, with 34 cases in each group. The control group was bismuth quadruplicate Program treatment, the experimental group in the control group on the basis of Pefki adjuvant therapy, the clinical efficacy of the two groups were compared. Results The therapeutic efficacy of the experimental group was 91.18%, which was significantly higher than that of the control group (73.53%, P <0.05). There was no significant difference between the two groups in blood zinc concentration before treatment; in the experimental group 2 weeks and 4 weeks after treatment, (P <0.05). The incidence of adverse reactions in the experimental group after treatment was 14.71%, which was significantly lower than that in the control group (35.92%, P <0.05). Conclusion The elderly peptic ulcer patients with HP infection in the bismuth quadruple regimen based on the combination of Peifei Kang adjuvant therapy with satisfactory results, the incidence of adverse reactions is low, it is worth promoting the application.